Chase Pharmaceuticals Corporation, Inc.

While clearly lagging behind their US counterparts, European biotechnology companies and medtech firms across all stages of development can still attract significant venture capital if they are innova

Financings Biopharma companies closed out 2016 with $9.6 billion in financing. ( See Exhibit 1. ) Not only was this a 30% increase over Q3's $7.4 billion, it was also the strongest quarter of the year

IN VITRO DIAGNOSTICS Alliances Allergan PLC T2 Biosystems Inc. T2 Biosystems Inc. and Allergan PLC are teaming up to develop a diagnostic panel to detect Gram-negative bacteria and antibiotic

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Nov. 21 and Dec. 2.